Stryker Corporation $SYK Shares Sold by Stack Financial Management Inc

Stack Financial Management Inc decreased its holdings in shares of Stryker Corporation (NYSE:SYK) by 1.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 73,347 shares of the medical technology company’s stock after selling 955 shares during the quarter. Stryker comprises 2.6% of Stack Financial Management Inc’s holdings, making the stock its 12th largest holding. Stack Financial Management Inc’s holdings in Stryker were worth $29,018,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. CCG Wealth Management LLC acquired a new stake in Stryker during the second quarter worth $216,000. Mitchell Sinkler & Starr PA increased its stake in Stryker by 2.0% during the second quarter. Mitchell Sinkler & Starr PA now owns 6,425 shares of the medical technology company’s stock worth $2,542,000 after acquiring an additional 124 shares during the last quarter. CWM LLC increased its stake in Stryker by 1.6% during the second quarter. CWM LLC now owns 17,652 shares of the medical technology company’s stock worth $6,984,000 after acquiring an additional 282 shares during the last quarter. OFI Invest Asset Management increased its stake in Stryker by 37.4% during the second quarter. OFI Invest Asset Management now owns 3,623 shares of the medical technology company’s stock worth $1,433,000 after acquiring an additional 986 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its stake in Stryker by 21.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 52,869 shares of the medical technology company’s stock worth $20,918,000 after acquiring an additional 9,436 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on SYK shares. Redburn Partners set a $420.00 target price on Stryker in a research note on Thursday, September 18th. Needham & Company LLC lifted their price objective on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Evercore ISI dropped their price objective on Stryker from $418.00 to $410.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Rothschild Redb raised Stryker to a “hold” rating in a research note on Thursday, September 18th. Finally, Wells Fargo & Company lifted their price objective on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $430.10.

Stryker Trading Down 1.5%

SYK opened at $364.77 on Monday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock has a market capitalization of $139.45 billion, a price-to-earnings ratio of 48.31, a PEG ratio of 2.63 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The business has a fifty day moving average price of $380.25 and a 200 day moving average price of $378.90.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same period in the previous year, the firm posted $2.81 EPS. Stryker’s revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s payout ratio is presently 44.50%.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.